

POLLER, Wolfgang
Projects C5, V1

NAME Wolfgang Ch. Poller, Prof. Dr. med. Date of birth: 29.03.1956 Gender: Male Nationality: German Four children (age: 11, 22, 25, 27) No paternal leaves		POSITION TITLE Professor of Medicine Director, Experimental Therapy Research Charité - Universitätsmedizin Berlin, CC 11 Medizinische Klinik II: Kardiologie und Pulmologie Hindenburgdamm 30, 12203 Berlin Germany Phone: +49-30-8445-2158 E-Mail: wolfgang.poller@charite.de	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Dept. of Cardiology and Pneumology, University Hospital, Freie Universität Berlin, Germany (H. Schultheiss)	Cardiologist	Since 06/1998	Cardiology, pneumology
Dept. of Biochemistry and Pathobiochemistry, University of Würzburg, Germany (U. Walther)		02/1995 – 05/1998	Biochemistry, cell and molecular biology
Dept. of Molecular Genetics, Southwestern Medical Center, Dallas, USA (J. Goldstein & M. Brown)		06/1993 – 01/1995	Molecular biology, genetics, virology
Dept. of Internal Medicine, University of Bochum Medical School, Bochum, Germany	Internist, Habilitation, Venia Legendi	01/1984-05/1993	Internal medicine, pneumology, clinical and molecular genetics
University of Essen Medical School, Germany, MD Thesis, Dept. of Haematology and Oncology (S. Öhl)	Approbation MD	09/1975 – 05/1982	Medicine

A. Positions and Honours

Positions

Since 07/2004	Secretary, CRC/TR 19 (funded by <i>German Research Foundation DFG</i>)
Since 07/2004	Director, Experimental Therapy Research, Dept. of Cardiology and Pneumology, CBF, Charité
Since 06/2000	Professor of Medicine and Senior Cardiologist, Dept. of Cardiology and Pneumology, Charité
06/1993 – 05/1996	Heisenberg Professor (funded by <i>German Research Foundation DFG</i>)
06/1992	Habilitation and Venia Legendi for Internal Medicine

Honours

2010	Circulation's Best Paper Award (<i>American Heart Association</i>)
2003	Heisenberg Award (<i>German Research Foundation DFG</i>)
1996 – 2001	Research Prizes from <i>Deutsche Gesellschaft für Innere Medizin</i> , <i>European Society of Cardiology</i> , and Johann-Lukas-Schönlein-Award

B. Five Most Important Publications (since 2008)

1. Suckau L., Fechner H., Chemaly E., Krohn S., Hadri L., Kockskämper J., Westermann D., Bisping E., Ly H., Wang X., Kawase Y., Chen J., Liang L., Sipo I., Vetter R., Weger S., Kurreck J., Erdmann V., Tschöpe C., Pieske B., Lebeche D., Schultheiss H.P., Hajjar R.J., Poller W. *Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.* Circulation 2009; 119: 1241-52. IF 14.816 (Circulation's Best Paper Award 2010).
2. Rother M., Krohn S., Kania G., Vanhoutte D., Eisenreich A., Wang X., Westermann D., Savvatis K., Dannemann N., Skurk C., Hilfiker-Kleiner D., Cathomen T., Fechner H., Rauch, Schultheiss H.P., Heymans S., Eriksson U., Scheibenbogen C., Poller W. *Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator.* Circulation 2010; 122: 2688-98. IF 14.429.
3. Pinkert S., Westermann D., Wang X., Klingel K., Dörner A., Savvatis K., Grössl T., Krohn S., Tschöpe C., Zeichhardt H., Kotsch K., Weitmann K., Hoffmann W., Schultheiss H.P., Spiller O.B., Poller W. & Fechner H. *Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.* Circulation 2009; 120: 2358-66. IF 14.816.
4. Skurk C., Wittchen F., Suckau L., Witt H., Noutsias M., Fechner H., Schultheiss H.P., Poller W. *Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy.* Eur Heart J 2008; 29: 1168-80. IF 8.917.
5. Löbel M, Bauer S, Meisel C, Eisenreich A, Kudernatsch R, Tank J, Rauch U, Kühl U, Schultheiss HP, Volk H, Poller W, Scheibenbogen C. *CCN1: A Novel Inflammation Regulated Biphasic Immune Cell Migration Modulator.* Cell Mol Life Sci 2012, Epub Apr 20. IF 7.847.

C. Planned FP3 Cooperations with other CRC/TR 19 Investigators

- A2 – Human cardiofibroblast cultures and their functional modulation by noncoding RNAs
- A3 – Genetic determinants of cardiac innate immunity
- B3 – Influence of the noncoding RNAs derived from human EMBx scans, and of ncRNA-blocking oligos upon immunoproteasomes in fibroblasts, AAV2/9 and AdV vector technology
- B5 – Regulation of noncoding RNA systems in transgenic B19V models and HCV infected cells, NGS
- B7 – Regulation of noncoding ncRNA systems in FOXO3a and APN deficient models, AAV2/9 and AdV vector technology
- C8N – ncRNAs (miRs, lncRNAs) as host factors modulating the course of viral infections
- Z1 – Continuation of mRNA and ncRNA array scans in human EMBx cohorts
- Z3 – Employment of animal core facilities
- Z4 – Mapping of miRs, lncRNAs, and CCNx gene in murine cardiomyopathy models
- Z5N – Specified proteomics studies and NGS to supplement the ncRNA target gene scans above

D. FP3-Relevant Current Cooperations with External Researchers

- Roger Hajjar (Mount Sinai School of Medicine, New York City, USA): Translational gene and RNAi therapy
- Peter Liu (Toronto General Hospital, Ontario, Canada): Innate immunity – chemotaxis interactions
- Stephane Heymans (Cardiovascular Research Center, Maastricht University): miRs, long noncoding RNAs
- Urs Eriksson (University of Zurich Medical School): Autoimmune heart disease
- Ziya Kaya (University of Heidelberg Medical School): cRGD and CCNx proteins in autoimmune disorders

E. Current and Previous Funding

Total financial support by research grants from German Research Foundation (DFG), Bundesministerium für Forschung und Technologie (BMBF), and charitable foundations: 5.2 Mio € until 10/2010. 3 current projects (A1, C5, V1) within the cardiovascular research network CRC/TR 19 (DFG-funded) are funded until 12/2012.